Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Metabolic syndrome

Metabolic syndrome is a clustering of cardiometabolic risk factors that includes abdominal adiposity, triglyceride and HDL cholesterol abnormalities, elevated blood pressure, and dysregulated glucose metabolism. The most widely shared operational definition in adults derives from the 2009 joint harmonization statement and requires at least three of five components. The term describes a common clinical phenotype, not a single disease with one mandatory cause or a pathognomonic test.

The diagnostic value lies in recognizing that findings often considered separately may reflect shared metabolic dysfunction and require coordinated intervention. The category does not replace diagnoses of diabetes, hypertension, obesity, or dyslipidemia, nor does it justify overlooking an important factor when the others do not meet their thresholds. Two people meeting three criteria may have very different absolute risks and treatment needs.

Frequency generally increases with age and adiposity but varies according to population, sex, criteria used, and waist circumference thresholds. Comparisons between studies therefore require attention to the definition adopted. A rise in prevalence may reflect actual changes in risk factors, changes in criteria, or both. Absence of the syndrome at one visit does not guarantee that the profile will remain favorable in subsequent years.

Etiology, pathogenesis, and pathophysiology

Insulin resistance is a central mechanism in many patients, but it has not been established as the sole cause of every diagnostic combination. Genetic predisposition, energy availability, inactivity, sleep, aging, and fat distribution interact with the ability of tissues to respond to insulin. Susceptibility varies: some people develop marked abnormalities with relatively modest excess weight, whereas others maintain metabolic compensation for longer.

In adipose tissue, cellular hypertrophy, reduced ability to generate new functional adipocytes, and inflammatory remodeling may impair safe lipid storage. Increased lipolysis releases fatty acids that reach the liver and skeletal muscle. Accumulation of lipid intermediates can interfere with insulin signaling, while reduced favorable mediators, including adiponectin, and increased inflammatory signals contribute to systemic dysfunction.

Visceral fat is particularly informative because it is associated with metabolic fluxes and cellular characteristics that differ from those of some subcutaneous depots. Waist circumference is an imperfect but accessible clinical indicator. It does not directly measure hepatic or epicardial fat and cannot distinguish all individual differences by itself; nevertheless, it reveals an unfavorable distribution that body mass index alone may fail to identify.

In the liver, resistance to insulin action promotes insufficient suppression of glucose production, while substrate availability and lipogenesis can support VLDL secretion. Excess triglyceride-rich particles alter lipid exchanges with LDL and HDL. LDL particles may become more numerous and relatively cholesterol-poor, with accelerated HDL catabolism: LDL-C may therefore incompletely represent atherogenic burden.

Endothelial dysfunction reflects a combination of reduced nitric oxide bioavailability, oxidative stress, and inflammatory signals. Compensatory hyperinsulinemia occurs in a system in which intracellular pathways do not necessarily have the same insulin sensitivity. Sympathetic activation, the renin–angiotensin–aldosterone system, renal sodium handling, and mechanical factors associated with adiposity contribute to elevated blood pressure. However, there is no obligatory sequence in which all components must appear in the same order.

Initially, the pancreas may maintain nearly normal blood glucose through increased insulin secretion. Progressive failure of compensation, influenced by predisposition and metabolic stress, facilitates prediabetes and type 2 diabetes. Normal fasting glucose does not exclude a postprandial abnormality, just as moderately increased glucose does not, by itself, demonstrate remaining secretory capacity. This heterogeneity limits the interpretation of a single insulin measurement.

The metabolic environment may be associated with a prothrombotic tendency through changes in platelet function, coagulation, and fibrinolysis. Such mechanisms explain part of the biological link to clinical events but do not independently justify antithrombotic therapy. Antiplatelet or anticoagulant prescriptions continue to depend on cardiovascular disease, bleeding risk, and specific indications.

The syndrome can be promoted or exacerbated by medications and associated conditions, such as glucocorticoids, some psychotropic drugs, obstructive sleep apnea, and endocrine disorders. Lipodystrophies and rare forms of severe insulin resistance can produce a similar profile without generalized obesity. Recognition of the phenotype must therefore not end etiological investigation when age, severity, fat distribution, or clinical signs are atypical.

Clinical manifestations, history, and physical examination

Presentation is often asymptomatic. Blood pressure, lipids, and glucose may remain abnormal for years before producing recognizable manifestations. No symptom can establish the diagnosis: fatigue, sleepiness, or increased hunger require separate interpretation. Symptoms of ischemia, progressive dyspnea, marked polyuria, or unintentional weight loss, however, call for evaluation of conditions that may already be present.

History taking includes weight trajectory, age at onset of abnormalities, family history of diabetes and premature disease, and previous lipid and blood pressure values. Gestational diabetes and polycystic ovary syndrome identify circumstances in which metabolic assessment may be particularly useful, although neither constitutes a diagnostic criterion for the syndrome. Menopause can alter fat distribution and risk without automatically explaining every new abnormality.

Assessment of diet and physical activity considers food quality, sugar-sweetened beverages, alcohol, sedentary behavior, and opportunities for movement. Sleep duration and regularity, shift work, and symptoms of sleep apnea may clarify aggravating factors. The discussion should reconstruct exposures and practical obstacles without automatically inferring habits from weight or attributing every abnormality to personal choice.

Physical examination measures waist circumference and blood pressure using standardized techniques. For waist circumference, the same anatomical landmark must be specified and consistently used: measurements at different sites may change classification near the threshold. Blood pressure is measured after rest, with an appropriately sized cuff and repeated readings. An incidental measurement is insufficient to establish chronic hypertension, although it may raise suspicion.

The examination looks for acanthosis nigricans, abnormal fat distribution, signs of hypercortisolism or hypothyroidism, and manifestations of vascular damage. These findings guide investigations, but their absence does not exclude the phenotype. BMI and muscle strength complement anthropometry: an older person with reduced lean mass may have substantial abdominal adiposity without a particularly high BMI.

Diagnostic criteria and limitations of classification

The 2009 harmonized definition requires at least three of the following: increased waist circumference, elevated triglycerides, low HDL-C, elevated blood pressure, and elevated fasting glucose. No individual component is mandatory. This differs from the 2005 IDF definition, in which central obesity was required along with two other components. Stating which system was used avoids comparing diagnoses made under different rules.

The threshold for triglycerides is at least 150 mg/dL, or specific treatment for this abnormality. HDL cholesterol must be below 40 mg/dL in men or 50 mg/dL in women, or relevant treatment must be present according to the definition. Simply taking a statin for elevated LDL does not automatically establish both lipid criteria: the abnormality prompting treatment and previous values must be known.

The blood pressure criterion is systolic pressure of at least 130 mmHg and/or diastolic pressure of at least 85 mmHg, or treatment for previously diagnosed hypertension. This is a threshold used to classify the syndrome, distinct from diagnostic thresholds and treatment targets in different hypertension guidelines. The fact that treatment currently keeps blood pressure normal does not erase the history of the treated component.

Fasting glucose must be at least 100 mg/dL, or treatment for hyperglycemia must be present. This value identifies one component of the phenotype and is insufficient to diagnose diabetes, for which separate criteria apply. HbA1c is useful for comprehensive assessment but does not automatically replace glucose in the harmonized definition's count. Previously diagnosed diabetes still requires its own clinical classification and treatment plan.

The waist circumference threshold is adapted to the population and reference adopted. In European populations, the IDF cutoffs of at least 94 cm for men and 80 cm for women are commonly used; traditional US criteria use 102 and 88 cm. These values are not interchangeable: they alter sensitivity and prevalence. Different thresholds may be indicated in other populations, so ancestry and context should be specified without resorting to one universal cutoff.

Counting the components means that different combinations are possible. A person with abdominal adiposity, elevated blood pressure, and dysglycemia does not necessarily have the same lipoprotein burden as someone with both lipid abnormalities and a modestly increased waist circumference. Age, smoking, LDL, kidney function, and event history are not all captured by the five criteria, despite their major prognostic importance. The binary classification therefore does not measure all aspects of severity.

Diagnosis does not require insulin measurement or HOMA-IR. The hyperinsulinemic–euglycemic clamp is a physiological reference for studying insulin sensitivity but is not a routine clinical test for this purpose. Indices based on glucose and insulin are influenced by assay, population, and beta-cell function and have no universal threshold for confirming the syndrome. Ordering them automatically may add ambiguity rather than precision.

Critical appraisal of the category has shown that its incremental predictive value over individual factors and risk models is inconsistent. Insulin resistance is not directly measured, and dichotomization loses information: triglycerides of 149 and 151 mg/dL do not represent two biologically separate conditions. Classification remains useful for recognizing a cluster of problems, while treatment intensity and prognosis require continuous measurements and clinical context.

These criteria apply to adults. They must not be transferred unchanged to children, in whom growth, puberty, and percentiles affect the interpretation of blood pressure and anthropometric measurements. Pregnancy also requires specific pathways. In patients with acute illness or recent treatment changes, component stability should be documented before giving a single measurement a permanent meaning.

Further investigations and risk assessment

Once the phenotype is recognized, the goal is to establish which diseases are already present. Confirmation of diabetes uses glucose, HbA1c, or an oral glucose tolerance test in appropriate settings; blood pressure may require home or ambulatory monitoring. A complete lipid profile distinguishes increased remnants from substantial concurrent hypercholesterolemia. Non-HDL cholesterol and apoB are particularly informative when triglycerides make LDL-C less representative.

Kidney assessment includes creatinine and eGFR and, particularly in diabetes, hypertension, or suspected nephropathy, albuminuria. Abnormal results must be confirmed and contextualized because intense exercise, infection, and decompensation can temporarily alter albumin excretion. Kidney involvement increases risk and may change medication choices even when the syndrome's five components are not particularly pronounced.

Metabolic dysfunction-associated steatotic liver disease may require assessment of fibrosis risk through appropriate noninvasive pathways. Normal transaminases do not exclude significant liver disease; a positive ultrasound alone does not establish stage. Investigation is coordinated with the metabolic profile and other possible causes of liver injury, without automatically equating metabolic syndrome with steatohepatitis.

Endocrine causes are investigated when the history and signs make them plausible. Hypothyroidism, hypercortisolism, and some medications may explain important components and require targeted interventions. Severe insulin resistance in someone with little subcutaneous adipose tissue should prompt consideration of lipodystrophy. Cortisol assays, hormone panels, or genetic tests need not be ordered indiscriminately for every patient meeting three criteria.

Atherosclerotic risk is assessed using appropriate models and clinical categories, incorporating factors not included in the syndrome. Documented coronary or peripheral arterial disease changes preventive management more than the simple count of components. Subclinical imaging is selective and useful when it may change a decision; it is not a prerequisite for treating clearly uncontrolled hypertension, diabetes, or LDL cholesterol.

The cardiovascular–kidney–metabolic framework proposed by the AHA broadens assessment to kidney function and subclinical or established heart disease. It is not a new name for the same five criteria. A person may fall within one of the framework's stages without meeting the traditional metabolic syndrome definition; the two tools have partially different purposes and must not be mechanically equated.

Treatment and monitoring

Management addresses both shared determinants and individual components. Nutritional treatment, exercise, and reduction of adiposity when indicated may improve several abnormalities simultaneously, but there is no drug that everyone should receive to “treat the syndrome.” Therapeutic indications follow obesity, blood pressure, diabetes, lipoproteins, organ damage, and overall risk, without waiting until each abnormality becomes severe.

A Mediterranean-style diet, tailored to energy requirements, emphasizes vegetables, legumes, minimally refined grains, nuts, and unsaturated fats while limiting sugar-sweetened drinks, excess salt, and energy-dense foods. A calorie deficit is helpful when fat mass needs to be reduced, but dietary quality and sustainability remain relevant even at a stable weight. Indiscriminately cutting fat and replacing it with refined carbohydrates may worsen the triglyceride component.

Physical activity improves insulin sensitivity, cardiorespiratory fitness, and blood pressure. For many adults, the reference is at least 150 minutes of moderate aerobic activity per week, complemented by resistance exercise and less sedentary time; the amount and progression depend on clinical status and limitations. Beneficial effects do not necessarily require visible weight loss. Chest pain or disproportionate dyspnea should be evaluated before markedly increasing exercise intensity.

In the Diabetes Prevention Program, an intensive program aiming for 7% weight loss and at least 150 minutes of activity per week reduced diabetes incidence more than metformin alone in the studied population at high glycemic risk. Long-term cardiovascular follow-up did not show a significant reduction in events with either intervention compared with the original comparison group. Preventing the onset of diabetes remains important, but does not justify replacing blood pressure and lipid management with glycemic prevention alone.

Metformin may be considered to prevent or delay diabetes in people with high-risk prediabetes. The ADA 2026 Standards particularly highlight adults aged 25–59 years with BMI at least 35 kg/m², higher glycemic values such as fasting glucose at least 110 mg/dL or HbA1c at least 6.0%, and people with a history of gestational diabetes. These features guide clinical selection and do not make the drug an automatic therapy for every case of metabolic syndrome. Kidney function, tolerability, and possible vitamin B12 deficiency with prolonged use are part of management; existing diabetes, by contrast, requires its own therapeutic pathway.

Treatment of obesity may include medications or metabolic surgery when criteria are met. These strategies are selected not by the number of syndrome criteria but by the severity of adiposity, complications, and expected benefit. Reducing visceral fat is useful, while preserving lean mass, strength, and nutritional adequacy protects against adverse consequences of poorly managed weight loss.

For blood pressure, recommended targets and drug combinations are based on clinical context. The 130/85 threshold used to classify metabolic syndrome is not a mandatory treatment target. Diabetes, albuminuria, coronary artery disease, or heart failure influence drug class selection; ACE inhibitors or angiotensin receptor blockers have a particular role in several of these settings, without making other effective classes inappropriate when needed. Orthostatic tolerability deserves attention in older adults and with combinations.

Treatment of dyslipidemia prioritizes atherogenic particles and risk. Statins are used when indicated, possibly combined with other drugs to achieve the required control. Low HDL-C does not call for treatment solely to raise its numerical level, and moderate triglyceride elevation does not automatically require adding a fibrate. Severe forms, however, require prevention of pancreatitis; cardiovascular indications for icosapent ethyl are limited to appropriate populations.

Thrombotic prevention follows its own indications. In the absence of cardiovascular disease, aspirin is not prescribed merely because the syndrome is present; potential benefit must be weighed against bleeding risk. Smoking cessation remains a priority even though smoking is not one of the five criteria. Treatment of sleep apnea, reduction of excessive alcohol intake, and review of aggravating medications complete selected interventions.

Follow-up assesses relevant components, risk, and the feasibility of the plan. Weight and waist circumference, blood pressure, blood glucose or HbA1c, lipids, and kidney function are rechecked at intervals appropriate to severity and treatment changes. If the number of criteria falls below three, the improvement should be recognized, but the history of abnormalities and medication effects remain part of interpretation. Losing the diagnostic label does not automatically justify stopping effective therapies.

Prognosis and complications

The syndrome is associated with an increased likelihood of type 2 diabetes and cardiovascular disease, but the increase is not the same for every combination. Age, duration, intensity of individual factors, and conditions excluded from the definition modify outcomes. The most useful prognostic information comes from integrating the phenotype with actual diagnoses and absolute risk, rather than merely belonging to the category.

Vascular complications include coronary artery disease, cerebrovascular events, and peripheral arterial disease. Heart failure and kidney disease may develop through pathways shared with hypertension, diabetes, and adiposity. They must not automatically be attributed to an undifferentiated syndrome: identifying their mechanisms enables selection of treatments with demonstrated benefits for the affected organ and relevant outcomes.

Progressive liver disease and functional limitations are additional aspects of the disease burden. Some frequently associated conditions, such as steatosis or sleep apnea, may precede the diagnosis of the syndrome and are not necessarily direct consequences of it. Distinguishing shared factors, comorbidities, and complications prevents overly simplistic causal explanations.

Early intervention can change the clinical trajectory, particularly when it combines lifestyle improvements with treatment of risk factors that are already present. Prevention need not wait for the third criterion to appear. Recognition of this cluster provides an opportunity for more coherent and sustained care while basing each decision on the specific condition and available evidence.

References
  1. Alberti KGMM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
  2. Alberti KGMM et al. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366(9491):1059–1062.
  3. Kahn R et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289–2304.
  4. Ndumele CE et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635.
  5. Koskinas KC et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. European Heart Journal. 2024;45(38):4063–4098.
  6. Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337.
  7. McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018.
  8. Marx N et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043–4140.
  9. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  10. Ginsberg HN et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal. 2021;42(47):4791–4806.
  11. Soffer DE et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. 2024;18(5):e647–e663.
  12. Newman CB et al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3613–3682.
  13. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49.
  14. American Diabetes Association Professional Practice Committee for Diabetes. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S50–S60.
  15. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002;346(6):393–403.
  16. Goldberg RB et al. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022;145(22):1632–1641.
  17. Estruch R et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. The New England Journal of Medicine. 2018;378(25):e34.
  18. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22.
  19. Das Pradhan A et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. The New England Journal of Medicine. 2022;387(21):1923–1934.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.